PCD test provides definitive diagnosis of a rare disease
Answers from the Lab
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that can cause chronic coughing and frequent infections in the lungs, ears, throat and sinuses. In this test specific episode of the "Answers From the Lab" podcast, Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD).
"It's quite uncommon to encounter PCD, which is why getting the diagnosis right is so important," Dr. Maleszewski says. "Mayo Clinic is fortunate to have a team of seven pulmonary pathologists who are experts in this area."
Powerful electron microscopy is used to identify defects in cilia — the tiny, hair-like structures that help expel inhaled particulates. "Based on the morphological abnormalities we may see, we are able to make a definitive diagnosis of PCD," Dr. Aubry says.
Mayo Clinic has endorsed the standard diagnostic guidelines provided by the Primary Ciliary Dyskinesia Foundation (PCDF) and incorporated them into the laboratory's diagnostic reporting. "The center of excellence designation is a reflection of our testing and diagnostic acumen," Dr. Maleszewski says.
Listen to learn more about Mayo Clinic Laboratories' definitive diagnostic test for PCD.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Providing information to aid in the diagnosis of medical disorders such as storage diseases, CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), and primary ciliary dyskinesia
Analytic time: 5 to 10 days
Days performed: Monday through Friday
PATHC | Pathology Consultation
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.